Baseline NS5A resistance associated substitutions may impair DAA response in real‐world hepatitis C patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-9071|90|3|532-536

ISSN： 0146-6615

Source： JOURNAL OF MEDICAL VIROLOGY, Vol.90, Iss.3, 2018-03, pp. : 532-536

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A‐Y93

By  

JOURNAL OF MEDICAL VIROLOGY, Vol. 90, Iss. 4, 2018-04 ,pp. : 736-744

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed

By Yoshida Kanako   Hai Hoang   Tamori Akihiro   Teranishi Yuga   Kozuka Ritsuzo   Motoyama Hiroyuki   Kawamura Etsushi   Hagihara Atsushi   Uchida-Kobayashi Sawako   Morikawa Hiroyasu   Enomoto Masaru   Murakami Yoshiki   Kawada Norifumi  

International Journal of Molecular Sciences, Vol. 18, Iss. 5, 2017-05 ,pp. : 962-962

MDPI

Access to resources Recommend Favorite

Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy

By  

JOURNAL OF MEDICAL VIROLOGY, Vol. 87, Iss. 11, 2015-11 ,pp. : 1913-1920

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy

By Nakamoto Shingo   Imazeki Fumio   Arai Makoto   Yasui Shin   Nakamura Masato   Haga Yuki   Sasaki Reina   Kanda Tatsuo   Shirasawa Hiroshi   Yokosuka Osamu  

International Journal of Molecular Sciences, Vol. 16, Iss. 9, 2015-09 ,pp. : 21177-21190

MDPI

Access to resources Recommend Favorite

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

By Kanda Tatsuo   Yasui Shin   Nakamura Masato   Suzuki Eiichiro   Arai Makoto   Ooka Yoshihiko   Ogasawara Sadahisa   Chiba Tetsuhiro   Saito Tomoko   Haga Yuki   Takahashi Koji   Sasaki Reina   Wu Shuang   Nakamoto Shingo   Tawada Akinobu   Maruyama Hitoshi   Imazeki Fumio   Kato Naoya   Yokosuka Osamu  

International Journal of Molecular Sciences, Vol. 18, Iss. 5, 2017-04 ,pp. : 906-906

MDPI

Access to resources Recommend Favorite